In the latest session, Tandem Diabetes Care Inc (NASDAQ: TNDM) closed at $32.46 up 5.39% from its previous closing price of $30.80. In other words, the price has increased by $+1.66 from its previous closing price. On the day, 2476612 shares were traded. TNDM stock price reached its highest trading level at $32.89 during the session, while it also had its lowest trading level at $30.91.
Ratios:
For a deeper understanding of Tandem Diabetes Care Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.02 and its Current Ratio is at 3.83. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.27.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Citigroup on August 04, 2023, Downgraded its rating to Neutral and sets its target price to $33 from $45 previously.
On May 05, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $45 to $33.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 27 ’23 when Allen Dick bought 5,000 shares for $18.96 per share. The transaction valued at 94,778 led to the insider holds 19,962 shares of the business.
Vosseller Leigh bought 6,200 shares of TNDM for $95,395 on Nov 08 ’23. The EVP & CHIEF FINANCIAL OFFICER now owns 11,860 shares after completing the transaction at $15.39 per share. On Nov 08 ’23, another insider, Hansen Shannon Marie, who serves as the Chief Legal Officer of the company, bought 1,935 shares for $15.44 each. As a result, the insider paid 29,884 and bolstered with 1,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 2.13B and an Enterprise Value of 2.08B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.85 while its Price-to-Book (P/B) ratio in mrq is 6.78. Its current Enterprise Value per Revenue stands at 2.78 whereas that against EBITDA is -10.56.
Stock Price History:
Over the past 52 weeks, TNDM has reached a high of $44.05, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 25.97, while the 200-Day Moving Average is calculated to be 24.82.
Shares Statistics:
For the past three months, TNDM has traded an average of 1.79M shares per day and 2.11M over the past ten days. A total of 65.55M shares are outstanding, with a floating share count of 65.19M. Insiders hold about 0.68% of the company’s shares, while institutions hold 109.03% stake in the company. Shares short for TNDM as of Feb 29, 2024 were 4.9M with a Short Ratio of 2.74, compared to 5.43M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.47% and a Short% of Float of 8.35%.
Earnings Estimates
There are 13 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.75 for the current quarter, with a high estimate of -$0.58 and a low estimate of -$0.85, while EPS last year was -$0.63. The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.35 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$1.36 and -$1.96 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$1.09, with 14 analysts recommending between -$0.7 and -$1.44.
Revenue Estimates
A total of 16 analysts believe the company’s revenue will be $174.22M this quarter.It ranges from a high estimate of $179.8M to a low estimate of $166M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $170.23M, an estimated increase of 2.30% from the year-ago figure. For the next quarter, 16 analysts are estimating revenue of $204.34M, an increase of 3.50% over than the figure of $2.30% in the same quarter last year. There is a high estimate of $220.15M for the next quarter, whereas the lowest estimate is $192M.
A total of 18 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $852.29M, while the lowest revenue estimate was $799M, resulting in an average revenue estimate of $844.35M. In the same quarter a year ago, actual revenue was $747.72M, up 12.90% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $940.09M in the next fiscal year. The high estimate is $1.01B and the low estimate is $903.3M. The average revenue growth estimate for next year is up 11.30% from the average revenue estimate for this year.
